While the efficacy of the rotigotine transdermal patch on motor aspects of Parkinson’s disease is well-established, the awareness of its impact on a wide range of non-motor symptoms is limited.

The rotigotine transdermal patch may be beneficial for the treatment of sleep impairment due to nocturnal motor symptoms and early-morning off; in addition, emerging results indicate efficacy for the management of fluctuation-related pain, apathy, and depression.

The rotigotine transdermal patch may play a key role in nil-by-mouth scenarios in acute management pathways in some countries, such as emergency situations or the intensive care environment, including during the current coronavirus disease 2019 (COVID-19) healthcare crisis.